Michael Panzara - Concepedia

Author

Michael Panzara

Also Known As

F. Lynn, Frances Lynn, M A Panzara, M. A. Panzara, M. Panzara, M.A. Panzara, MA Panzara, Michael A Panzara, Michael A. Panzara, Michael Panzara

Publications

14.1K

Citations

H-Index

Concepts

All Affiliations

Biogen (United States)Cleveland Clinic University College London Wave Life Sciences (United States)Stanford University

About

Michael Panzara is an author at Biogen (United States) specializing in medicine, immunology, and multiple sclerosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	3.3K
2	Allergy	2	2	118
3	Public Health	1	1	11
4	Allergy Medicine	1	1	43
5	Biostatistics	1	1	11

Michael Panzara

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Chris H. Polman, Paul O’Connor, Eva Havrdová, New England Journal of Medicine	2006	3.3K
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold, New England Journal of Medicine	2008	2.4K
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis Richard A. Rudick, William H. Stuart, Peter A. Calabresi, New England Journal of Medicine	2006	1.3K
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold, The Lancet RheumatologyRelapsing-remitting Multiple SclerosisImmunologyClinical TrialsTreatment Option	2012	1.2K
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Alasdair Coles, Cary Twyman, Douglas L. Arnold, The Lancet ImmunologyClinical TrialsNeurological ProgressDisease-modifying TherapyMultiple Sclerosis	2012	1.2K
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial Amit Bar‐Or, Peter A. Calabresi, Douglas L. Arnold, Annals of Neurology	2008	524
Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis Jorge R. Oksenberg, Michael Panzara, Ann B. Begovich, Nature Brain LesionsNeurological DisorderMedicineImmunologyBrain-immune Interaction	1993	392
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS David H. Miller, Derek Soon, Kryshani Fernando, Neurology	2007	330
The incidence and significance of anti-natalizumab antibodies Peter A. Calabresi, Gavin Giovannoni, Christian Confavreux, Neurology	2007	329
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function Bhupendra Khatri, S. Man, Gavin Giovannoni, Neurology	2009	276

Page 1